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Abstract
Previous reports have implicated an induction of genes in IFN/STAT1 (Interferon/STAT1) signaling in radiation resistant and
prosurvival tumor phenotypes in a number of cancer cell lines, and we have hypothesized that upregulation of these genes
may be predictive of poor survival outcome and/or treatment response in Glioblastoma Multiforme (GBM) patients. We have
developed a list of 8 genes related to IFN/STAT1 that we hypothesize to be predictive of poor survival in GBM patients. Our
working hypothesis that over-expression of this gene signature predicts poor survival outcome in GBM patients was
confirmed, and in addition, it was demonstrated that the survival model was highly subtype-dependent, with strong
dependence in the Proneural subtype and no detected dependence in the Classical and Mesenchymal subtypes. We
developed a specific multi-gene survival model for the Proneural subtype in the TCGA (the Cancer Genome Atlas) discovery
set which we have validated in the TCGA validation set. In addition, we have performed network analysis in the form of
Bayesian Network discovery and Ingenuity Pathway Analysis to further dissect the underlying biology of this gene signature
in the etiology of GBM. We theorize that the strong predictive value of the IFN/STAT1 gene signature in the Proneural
subtype may be due to chemotherapy and/or radiation resistance induced through prolonged constitutive signaling of
these genes during the course of the illness. The results of this study have implications both for better prediction models for
survival outcome in GBM and for improved understanding of the underlying subtype-specific molecular mechanisms for
GBM tumor progression and treatment response.
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Glioblastoma multiforme (GBM) remains the most common
primary brain malignancy and carries the worst prognosis [1]. In
recent years, several groups have investigated molecular and
genetic characteristics of these tumors in order to develop both
prognostic and predictive biomarkers. Most of the biomarkers
identified to date have been prognostic in that they help to
determine estimates of survival (prognosis) independent of
treatment. Predictive markers, on the other hand, inform
regarding sensitivity to specific therapies. Predictive markers in
GBM are quite limited, with the only established marker being the
methylation status of O(6)-methylguanine-DNA-methyltransferase
(MGMT) which is a predictor of temozolomide [2] and radiation
resistance [3]. However, studies from other cancers have identified
predictive markers with potential application in GBM.
Signal transducer and activator of transcription 1 (STAT1), the
putative downstream effector of interferon (IFN), and interferon-
related genes have been identified as key regulators of radiation
resistance in preclinical models of head and neck squamous cell
cancer [4,5] and have been identified as radiation inducible in a
wide variety of cancer cell lines, including glioma [5,6]. Moreover,
IFN/STAT1 signaling has been associated with not only
metastatic potential, but also resistance to adriamycin chemother-
apy and radiation in a murine model of melanoma [7].
Importantly, these results have been confirmed in breast cancer
patients in which an ‘‘IFN-related DNA damage resistance
signature’’ (IRDS) provided an improved outcome classification
in terms of locoregional failure following adjuvant radiation and
efficacy of adjuvant chemotherapy [8]. Because of the results of
these experimental studies, and the observation that the IRDS
gene expression pattern is also seen in high grade glioma primary
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29653tumors [8], we have hypothesized that up-regulation of these genes
in GBM patients may be predictive of poor survival outcome and/
or treatment response. To test this hypothesis, we have utilized
gene expression data and clinical data from the Cancer Genome
Atlas Project (http://cancergenome.nih.gov/) to test the associa-
tion between an IFN/STAT1 pathway signature derived from the
IRDS with survival outcome of GBM patients.
We have constructed an 8 gene set associated with the IFN/
STAT1 pathway: STAT1, IFI44, IFIT3, OAS1, IFIT1, ISG15,
MX1, and USP18 [8]. Survival analysis as a function of gene
expression data was performed used Cox Proportional Hazards
models. We have created single gene models, and we have created
multiple gene models with various model selection techniques. In
addition, previous reports indicate the presence of molecular
subtypes of GBM (Classical, Mesenchymal, Proneural, and Neural
[9]) which show distinct clinical and molecular characteristics.
Thus we have also performed subtype-specific survival analysis to




S i n g l eg e n eC o xm o d e l sw e r eb u i l tw i t ha g ea sac o v a r i a t ef o re a c ho f
the genes in the hypothesized signature except for IFIT3 which was
missing from the gene-averaged expression data set. Table 1 shows the
resulting models in the full data set (all samples) and the Proneural data
set. The results for the other three subtypesare in Table S1.These results
show an increased hazard for death for all of these genes in both the full
and Proneural data sets, with significance at a level of 0.05 found for
MX1 in the full data set, and significance found for all genes except IFIT1
and USP18 in the Proneural data set. The full and Proneural models are
concordant, with MX1 showing the s t r o n g e s te f f e c ti nb o t h ,a n da
s i m i l a rr e l a t i v er a n k i n go fg e n ee f f e c t si ne a c h .T h es i n g l eg e n er e s u l t s
were not significant in the other subgroups tested (with the exception of
the Neural group which had a significant effect for USP18, HR=1.75,
p=0.02). In order to visualize the survival effects for the various single
gene models, predicted survival curves for individuals at the 3
rd quartile
(75%) and 1
st quartile (25%) of the expression distribution for each gene
were graphed in Figure 1 for the Proneural model and in Figure S1 for
the full model. The survival curves were generated using the median age,
see details in the Methods section.
Multiple Gene Models
Because the genes in the STAT1/IFN signature are highly
correlated (see correlation among genes in the full and Proneural
data sets in Tables S2 and S3) and functionally related, we
expected that a multi-gene model may take into account the
complexities of the joint effects on survival of this signature. We
used various methods for creating multi-gene models including
stepwise regression with and without age adjustment, and elastic
net which estimates a joint multi-gene model with a penalty for
larger coefficients and more complex models. The results are
shown in Table 2 which shows analysis in the full data set (all
samples) and analysis in each of the four subtypes.
The first observation is that the multi-gene models confirm the
single-gene resultswhichshow that the effectofthisgene signature is
most pronounced in the Proneural subgroup. In addition, the MX1
gene shows the largest effect in both the full and Proneural models
(as it did in the single gene analysis). Of note is the fact that IFIT1
and USP18 are both added to the Proneural model for all three
model selection methods (and IFIT1 is also added to the full model
for the stepwise methods); these genesshownon-significant effects in
the single-gene analysis, but in the multi-gene analysis show effects
in the opposite direction (high expression increases survival). Thus
the multi-gene analysis shows that IFIT1 and USP18 may
additionally be involved in survival prediction, even though they
were not significant in the single-gene analysis. The inclusion of
these genes in the multi-gene model is probably due to IFIT1 and
USP18 having effects in the opposite direction (protective) after
accounting for the main effect of MX1, a complex phenomenon
that can only be captured with a multi-gene model.
The elastic net results for the Proneural model show that a
similar gene set is selected (as compared to the stepwise results),
thus showing consistency between these two model selection
techniques; however, more genes are added in the elastic net
model with a higher R
2 (82.1% as compared with 59.1% in the
stepwise model). Another observation is that the models with and
without age are similar, with the same genes added and with the
same effect direction. This result indicates that the gene signature
proposed here gives predictive value above and beyond age, the
most commonly-used risk predictor for GBM, and furthermore,
the effects on survival for these genes are largely independent of
age. Another observation is that the models for the Neural and
Proneural subtypes are quite different, with effects in the opposite
direction for several genes, illustrating that the effect of this gene
signature on survival is highly subtype-dependent. Figure 2
summarizes the results of the stepwise models in terms of total
explained variance (R
2) with and without age for the full analysis
and analysis in each subgroup.
A test of the proportional hazards assumption of the Cox model,
which requires that the hazard ratio for a term in the model be
constant in time, was Tables S4 and S5, respectively). These tests
showed that age showed a significant violation of the proportional
hazards assumption, but none of the genes showed significant
violations. To account for the proportional hazards violation for
age, we examined the models without age, which showed no such
violation (See Table S9 and Table 2, column 2). The full model
and Proneural model showed the same genes added to the model
with effects in the same direction and of similar size. Thus we
conclude that the predictive value of these multi-gene models is
present even when removing age which shows a proportional
hazards violation.
Probe Set Gene Expression Analysis
In order to verify that the survival models built here are valid in
multiple gene expression platforms and not dependent on the
specific algorithm used to build a gene-averaged, cross-platform
gene signature [9], we also built survival models that included
probe set expression data from two of the gene expression
platforms in the TCGA project (Affymetrix and Agilent). Elastic
net was used to build multi-gene models from the probe sets
assigned to the eight genes in our signature along with age, and the
resulting hazard ratios and model R
2 values are shown in Table S6
for the Affymetrix probe sets and Table S7 for the Agilent probe
sets. In comparing the discovered models for probes sets with the
gene-averaged models (Table 2 column 3), there is remarkable
agreement in terms of the genes (probe sets) added to the models,
direction of effects, and total explained variance (R
2). Thus we
conclude that the models built here are robust to platform used for
gene expression profiling, with similar models discovered regard-
less of platform or gene expression summarization method.
Evaluation of Survival Prediction Model for Proneural
Subtype in Validation Data Set
In order to test the predictive ability of our discovered models in
an independent data set not used for model building, we generated
predicted survival times in a validation data set using the model
IFN/STAT1 Survival Gene Signature in Proneural GBM
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genes up to IFI44 (i.e. age, MX1, IFIT1, and IFI44). We chose this
model because USP18 (the gene added after IFI44) is not present
in the validation set, and we wanted the models between
prediction and validation to be comparable. Plots of predicted
versus actual survival time for both the discovery and validation
data sets are shown in Figure 3. It can be seen from this figure that
the predictive value of the multi-gene model in the Proneural
subtype is retained in the validation set, with a correlation between
predicted and actual survival times of 0.64 (95% confidence
interval of 0.45, 0.77) in the discovery set and 0.39 (95%
confidence interval of 0.16, 0.57) in the validation set. Thus
although the prediction is a bit lower in the validation than the
training set, as usually occurs when moving from training to testing
sets, the 95% confidence interval for the correlation is greater than
zero for both. If prediction models with just age are built, then a
correlation between predicted and actual survival times of 0.45
(95% confidence interval of 0.21, 0.64) and 0.30 (95% confidence
interval of 0.07, 0.51) are obtained in the discovery and validation
sets, respectively, and thus higher predictive accuracy is achieved
using the discovered gene expression model for prediction. Table
S8 shows the results of directly fitting the discovered Cox model
for the discovery Proneural sample in the validation Proneural
sample (and also including terms to allow for potential study-
specific survival rates in the four different studies included in the
validation sample). The fitted model results are shown as hazard
ratios and p-values for all of the parameters as well as total
explained variance (R
2) for the full model (28.2%) and a reduced
model without the gene expression variables (20.3%).
Network Analyses and Biological Interpretation of STAT1/
IFN Gene Signature
In order to provide biological context and interpretability of the
STAT1/IFN gene signature, functional annotation networks were
produced using IPA (Ingenuity Pathway Analysis, see Methods
section) for the eight gene signature. Figure 4A illustrates the set of
known functional relationships among the eight genes in the
STAT1/IFN gene set and Figure 4B shows how these genes
interact in the Interferon signaling cascade. The genes in the gene
signature are bold-faced and underlined in 4A and bold-faced and
shaded in 4B. In 4A, additional genes (a maximum of ten) are
added by IPA to make connections among query (signature) genes
separated by at most one gene. The IPA networks show most of
these genes to be downstream targets of the Interferon/STAT1
Table 1. Single Gene Cox Proportional Hazards Models with
age adjustment for seven genes available in the TCGA
discovery (gene-averaged) data set.
Gene All Proneural
HR p value HR p value
IFI44 1.14 (0.98,1.33) 0.089 1.55 (1.16,2.06) 0.003
IFIT1 1.03 (0.92,1.16) 0.579 1.04 (0.80,1.33) 0.789
ISG15 1.14 (0.99,1.30) 0.060 1.50 (1.14,1.96) 0.004
MX1 1.15 (1.01,1.30) 0.034 1.86 (1.37,2.52) ,.0001
OAS1 1.14 (0.97,1.33) 0.097 1.70 (1.19,2.41) 0.003
STAT1 1.14 (0.94,1.37) 0.170 1.62 (1.11,2.35) 0.011
USP18 1.07 (0.87,1.31) 0.513 1.09 (0.69,1.70) 0.710
Estimated hazard ratios (95% confidence interval in parentheses) and p-values
are given for each gene, and significant effects are shown in boldface.
doi:10.1371/journal.pone.0029653.t001
Figure 1. Survival Curves for age-adjusted Cox Proportional Hazard models for 1
st quartile (red) and 3
rd quartile (blue) gene
expression values for each gene in the Proneural subtype.
doi:10.1371/journal.pone.0029653.g001
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STAT1, which are predicted to be up-regulated with increased
Interferon signaling, are shown to have significantly increased
hazard ratios in the single gene analysis (Figure 1 and Table 1).
Interestingly, the two genes not found to be significant in the single
gene analysis, USP18 and IFIT1, are found to be significant in the
multi-gene analysis for Proneurals (Table 2), with effects in the
opposite direction (higher expression is protective, after correcting
for the MX1 main effect). USP18 is a ubiquitin specific peptidase
which specifically processes ISG15 (shown with the protein-protein
interaction in Figure 4). USP18 has been demonstrated to be a
regulator of susceptibility for interferon signaling and drug-
induced apoptosis [10], and also to regulate EGFR-related
expression and cancer cell survival [11], and thus may serve as
an important counterbalance in this molecular signature. Inter-
estingly, in the Bayesian Networks discovered for the full and
Proneural data sets, shown in Figure 5 (A and B, respectively), the
USP18-ISG15 interaction and the STAT1-ISG15 interactions are
discovered, which lends support to the role of USP18 as a
modulator of STAT1 signaling. Indeed these interactions are
documented to exist as listed in Figure 4A (STAT1 -. ISG15 is a
known protein-DNA interaction, and USP18 – ISG15 is a known
protein-protein interaction). The Bayesian Networks also show
connections between USP18 and IFIT1 (either directly in the full
network or indirectly through ISG15 in the Proneural network),
which may provide an explanation for why IFIT1 has a negative
(protective) effect on survival in the Proneural subtype, as does
USP18, after taking into account the MX1 main effect (see
Table 2). Another general observation in comparing the two
discovered networks in Figure 5 is that many of the edges overlap,
suggesting that the Proneural subtype mechanisms dominate the
behavior of the full sample.
Discussion
Survival models for GBM patients from the Cancer Genome
Atlas Project (TCGA) have been constructed using a hypothesized
gene expression signature shown in previous experimental cell line
studies to predict for radiation and chemotherapy resistance in
tumor cells. Survival models were built for all GBM patients and in
subtype-specific analyses, with and without age as a covariate,
using single gene and multi-gene models. Our working hypothesis
that over-expression of this gene signature predicts poor survival
outcome in GBM patients was confirmed. In addition, it was
demonstrated that the dependence of survival outcome on IFN/
STAT1 gene expression was highly subtype-dependent, with
strong dependence in the Proneural subtype and no detected
dependence in the Classical and Mesenchymal subtypes. Addi-
tionally, the gene expression signature was shown to be almost
invariant with age in predicting survival outcome, with little
change in the signature in models with and without age. The
multi-gene model constructed in the discovery set for the
Proneural subtype was confirmed in an independent validation
data set with a correlation between predicted and actual survival
time of 0.39.
The dependency on the Proneural subtype for the IFN/STAT1
gene set highlights the context specificity for this signaling cascade
and helps explain the apparent paradoxical downstream effects
that IFN signaling promotes. In many model systems, IFN/
STAT1 signaling promotes anti-proliferation and pro-apoptosis
predominantly through the transcriptional modulation of key
components of growth and apoptosis signaling including IRF1,
Fas, FasL, TRAIL, p21waf1, and caspase-2, -3, and -7 [12,13].
For this reason, it has been traditionally thought that STAT1 may
Table 2. Multi-gene Cox Proportional Hazards models for all
samples and specific subtypes using three different model
selection methods: Stepwise regression with age as a
covariate (SW with age), stepwise regression without age (SW
no age), and Elastic Net.
HR (LB,UB)
Model Term SW with age SW no age Elastic Net
All Age 1.03 (1.02,1.04) NI 1.02
MX1 1.29 (1.06,1.57) 1.44 (1.19,1.75) 1.09
IFIT1 0.88 (0.74,1.04) 0.79 (0.67,0.94) NI
R
2 19% 7% 31%
Proneural Age 1.04 (1.02,1.06) NI 1.03
MX1 2.12 (1.13,3.97) 2.44 (1.48,4.03) 1.88
IFIT1 0.42 (0.23,0.76) 0.6 (0.4,0.92) 0.64
IFI44 1.82 (0.97,3.41) 2.3 (1.28,4.15) 1.5
USP18 0.46 (0.23,0.95) 0.36 (0.19,0.68) 0.6
ISG15 1.93 (0.77,4.81) NI 1.27
OAS1 NI NI 1.02
R
2 61% 47% 82%
Neural Age 1.06 (1.01,1.1) NI 1.03
USP18 4.06 (1.47,11.19) 1.65 (1.04,2.62) 1.3
MX1 0.48 (0.22,1.05) NI NI
IFIT1 NI NI 1.06
IFI44 NI NI 1.05
R
2 37% 14% 44%
Classical Age 1.01 (0.99,1.04)
R
2 3%
Mesenchymal Age 1.05 (1.02,1.08) 1.03
R
2 15% 24%
Hazard ratios with confidence limits are given for each term added to each
model. If the term was not added to a given model, NI is displayed for ‘‘not
included’’. The total explained variance for each model (R
2) is also displayed.
doi:10.1371/journal.pone.0029653.t002
Figure 2. Bar plot of total explained variance (R
2) for survival
models discovered using stepwise selection with genes only
(‘‘No Age’’) or with genes and age (‘‘Age’’) for all GBM patients
and by subtype.
doi:10.1371/journal.pone.0029653.g002
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demonstrated that prolonged IFN signaling or constitutive STAT1
signaling promotes not only tumor growth, but also resistance to
chemotherapy and radiation [4,5,7,8,14]. Given that the standard
of care for patients following surgical resection and histopathologic
diagnosis of GBM is involved field external beam radiotherapy
alone or concurrent with temozolomide chemotherapy [15,16] the
overall survival data for patients whose pretreatment gene profiling
was employed in the discovery and validation analyses described
here is likely consistent with the predictive importance of these
findings.
It has been hypothesized that constitutive activation of STAT1
promotes a ‘‘switch’’ from a cytotoxic signaling pathway to a pro-
tumor survival phenotype. We suspect that this switch may be
occurring in the Proneural subtype of GBM because it is this
subtype that is thought to be the predominant secondary GBM
subtype [9] that arises by progressive transformation from a lower
to a higher grade glioma. It is possible that the more chronic
natural history of the Proneural subtype yields a context in which
constitutive IFN/STAT1 signaling generates the chemotherapy/
radiation resistant phenotype. Indeed, only the Proneural subtype
of GBM showed no improvement in outcome with intensive
adjuvant therapy [9]. Therefore, targeting STAT1 for this
molecular subtype may reverse this resistance to chemoradiation.
A novel therapeutic approach for patients with GBM that has
recently gained favor is the use of oncolytic viruses [17,18],
reviewed in [19]. Although the outcomes from multiple clinical
trials have been less than optimal, there have been several reports
of long-term (.5 yrs) clinical remissions in an otherwise
unclassified cohort of patients. Whether or not GBM patients
who display an elevation in IFN/STAT1-mediated gene activa-
tion have a heightened resistance to virus-mediated infection and
oncolysis remains to be determined, but if this proves to be so, it
could form a rational basis for prescreening GBM patients for this
therapy. Speaking more generally, we are optimistic that the IFN/
STAT1 mechanism shown in this report to be related to disease
progression in Proneurals could be exploited in future research for
either tailored treatment selection in this subgroup or for rational
design of novel therapeutic agents.
Materials and Methods
Data
Clinical and gene expression data was obtained from the
Cancer Genome Atlas Project. Gene expression data from three
separate microarray platforms was summarized by gene using a
method described elsewhere [9]. In this list of genes one was
missing from the 8-gene set (IFIT3). The validation data set was
derived from four separate studies as described in [9]. The
summarized clinical data for the validation set was kindly provided
by Neil Hayes. In addition, gene expression data for individual
probe sets for the Affymetrix and Agilent platforms were analyzed
as well; these data were obtained through the TCGA data portal.
Of the 202 samples in the original data set, 2 were non-GBM, and
eight were removed for having prior glioma, leaving 192
individuals containing data for the gene-summarized gene
expression and clinical characteristics, and 191 individuals
containing gene expression data in the Affymetrix and Agilent
platforms. Filtering out prior glioma was performed to be
consistent with the original goals of the TCGA to characterize
primary GBMs. 246 individuals were included from the validation
data set. More detailed clinical characteristics of the both samples
are contained in [9]. In addition, the number of patients by
subtype are given in Table S9 for discovery and validation sets.
The assignment of subtype is done using a gene expression-based
classification algorithm in [8].
Statistical and Network Analysis
Single gene Cox proportional hazards models were fit using
Proc PHReg in SAS version 9.2 with predicted survival curves
generated using the median age and the 1
st and 3
rd quartiles of
gene expression for each gene. In particular, the survival curves
were predicted based on exponentiating Breslow’s baseline
cumulative hazard rate at a median value of age. The parameter
Figure 3. Graph of predicted and actual survival times in Proneural subtype for the discovery data set (left) and the validation data
set (right) using the age-adjusted stepwise selection model (up to IFI44). The correlation between predicted and actual survival values is
0.64 (0.45, 0.77) in the discovery set and 0.39 (0.16, 0.57) in validation set.
doi:10.1371/journal.pone.0029653.g003
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the genes in the hypothesized eight gene STAT1/IFN gene set (A) and that show the functional relationships among these genes as
they relate to Interferon signaling (B) (genes in eight gene signature are shaded).
doi:10.1371/journal.pone.0029653.g004
Figure 5. Discovered Bayesian Network for the full set of GBM (A) and the Proneural subtype (B). Growth-shrink algorithm was used and
80% bootstrap support for presence of edges and 50% bootstrap support for edge direction were required for the full sample (A), and 50% each were
required for the Proneural subtype (B). With the more stringent criteria for the Proneural subtype (80% bootstrap support for edge presence) the
OAS1-.MX1 and ISG15-.IFIT1 edges were discovered.
doi:10.1371/journal.pone.0029653.g005
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been estimated in the presence of the effect of age. For building
multi-gene models, forward stepwise regression using the Cox
proportional hazards model was performed using the coxph
routine in the Survival package in R version 2.10.1. The step
function in the R stats package was used to do forward selection
with the stopping criteria being a non-decreasing Akaike
Information Criteria (AIC) value. Model R
2 was calculated to
account for censoring using a formula given in [20]. Violation of
the proportional hazards assumption was tested using the cox.zph
function which computes a test for each model parameter and a
global model test using a method described in [21].
Penalized survival analysis using Elastic Net was performed using
the glmnet package in R. For generating predicted survival times
from the discovered multi-genic Cox models in both the discovery
and validation sets, a procedure described in [22] was used after
designating the exponential parametric form. The value of the
tuning parameter for the Elastic Net method is selected such that
mean cross-validation error is minimized. This was implemented
using the function cv.glmnet available in the package glmnet.
Functional annotation networks were generated using Ingenuity
Pathway Analysis or IPA (www.ingenuity.com), which provides a
graphical representation of the molecular relationships between
genes. The network was generated initially using the 8 gene set,
and was expanded with a maximum of 10 genes that are
connected to the initial genes. Molecules are represented as nodes,
and the biological relationship between two nodes is represented as
an edge (line). All edges are supported by at least 1 reference from
the literature, from a textbook, or from canonical information
stored in the Ingenuity Pathways Knowledge Base. Direct
relationships are indicated by solid lines and indirect through
dashed lines. Line beginnings and endings illustrate the direction
of the relationship (e.g. arrow head indicates gene A influences
gene B). Nodes are displayed using various shapes that represent
the functional class of the gene product. Edges are displayed with
various labels that describe the nature of the relationship between
the nodes (e.g., P for phosphorylation, T for transcription).
Bayesian Networks were discovered using the growth-shrink algorithm
i m p l e m e n t e di nt h ep a c k a g eB N L e a r nv e r s i o n1 . 9i nRw i t hac u s t o m
routine for finding bootstrap support for edge presence and direction.
Supporting Information
Figure S1 Survival Curves for age-adjusted Cox Proportional
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A_23_P815, A_23_P819, A_23_P404628, A_32_P99533, A_32_
P99534, NM_005101_1_144, and NM_005101_1_275), and for
IFIT3 (A_23_P35404, A_23_P35405, and A_23_P35412).
(DOC)
Table S8 Cox Proportional Hazard model for the Proneural
sample in the validation set using the stepwise selection variables
found for the Proneural sample in the discovery set (with the
exception of USP18 which is not present in the gene-averaged
validation gene expression sample, see Table 2), and including a
factor variable for study center to allow for study-specific survival
rates. Estimated hazard ratios and p values are shown for each
term in the model, and the full model R
2 as well as the reduced R
2
when only including age and center variables are shown.
(DOC)
Table S9 Patient Characteristics in discovery (TCGA) and
validation data sets. For the discovery set, only GBM samples
without prior glioma were used.
(DOC)
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